StockData
Biomerica Inc logo

Biomerica Inc (BMRA) stock

BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3055% below fair value
$1.10+0.01 (+0.92%)

Close on Nov 19, 2026Market cap $5.06MP/E –Yield –

Biomerica net income

Net income is the profit left for shareholders after every expense, interest and tax.

Biomerica's net income for the twelve months ending Aug 31, 2026 was -$5.01M. For fiscal 2026 it was -$3.78M. The highest annual figure on record is $548.44K in fiscal 2012.

Annual net income

PeriodPeriod endValueChange
FY2026May 31, 2026-$3.78M–
FY2025May 31, 2025-$4.97M–
FY2024May 31, 2024-$5.98M–
FY2023May 31, 2023-$7.14M–
FY2022May 31, 2022-$4.53M–
FY2021May 31, 2021-$7.45M–
FY2020May 31, 2020-$2.68M–
FY2019May 31, 2019-$2.39M–
FY2018May 31, 2018-$1.47M–
FY2017May 31, 2017-$908.56K–
FY2016May 31, 2016-$1.50M–
FY2015May 31, 2015-$331.41K–
FY2014May 31, 2014-$215.66K-140.2%
FY2013May 31, 2013$536.96K-2.1%
FY2012May 31, 2012$548.44K+248.3%
FY2011May 31, 2011$157.45K–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026-$1.23M-61700.0%
Q4 FY2026CQ2 2026May 31, 2026-$1.15M–
Q3 FY2026CQ1 2026Feb 28, 2026-$1.31M–
Q2 FY2026CQ4 2025Nov 30, 2025-$1.32M–
Q1 FY2026CQ3 2025Aug 31, 2025$2.00K–
Q4 FY2025CQ2 2025May 31, 2025-$1.54M–
Q3 FY2025CQ1 2025Feb 28, 2025-$1.16M–
Q2 FY2025CQ4 2024Nov 30, 2024-$950.00K–
Q1 FY2025CQ3 2024Aug 31, 2024-$1.32M–
Q4 FY2024CQ2 2024May 31, 2024-$1.42M–
Q3 FY2024CQ1 2024Feb 29, 2024-$1.92M–
Q2 FY2024CQ4 2023Nov 30, 2023-$1.51M–
Q1 FY2024CQ3 2023Aug 31, 2023-$1.13M–
Q4 FY2023CQ2 2023May 31, 2023-$1.79M–
Q3 FY2023CQ1 2023Feb 28, 2023-$1.65M–
Q2 FY2023CQ4 2022Nov 30, 2022-$1.63M–
Q1 FY2023CQ3 2022Aug 31, 2022-$2.07M–
Q4 FY2022CQ2 2022May 31, 2022-$1.76M–
Q3 FY2022CQ1 2022Feb 28, 2022-$104.17K–
Q2 FY2022CQ4 2021Nov 30, 2021-$1.13M–
Q1 FY2022CQ3 2021Aug 31, 2021-$1.54M–
Q4 FY2021CQ2 2021May 31, 2021-$1.71M–
Q3 FY2021CQ1 2021Feb 28, 2021-$2.12M–
Q2 FY2021CQ4 2020Nov 30, 2020-$1.72M–
Q1 FY2021CQ3 2020Aug 31, 2020-$1.89M–
Q4 FY2020CQ2 2020May 31, 2020-$824.69K–
Q3 FY2020CQ1 2020Feb 29, 2020-$860.93K–
Q2 FY2020CQ4 2019Nov 30, 2019-$485.26K–
Q1 FY2020CQ3 2019Aug 31, 2019-$506.30K–
Q4 FY2019CQ2 2019May 31, 2019-$785.33K–
Q3 FY2019CQ1 2019Feb 28, 2019-$678.75K–
Q2 FY2019CQ4 2018Nov 30, 2018-$477.24K–
Q1 FY2019CQ3 2018Aug 31, 2018-$451.74K–
Q4 FY2018CQ2 2018May 31, 2018-$667.62K–
Q3 FY2018CQ1 2018Feb 28, 2018-$322.49K–
Q2 FY2018CQ4 2017Nov 30, 2017-$268.66K–
Q1 FY2018CQ3 2017Aug 31, 2017-$207.06K–
Q4 FY2017CQ2 2017May 31, 2017-$345.82K–
Q3 FY2017CQ1 2017Feb 28, 2017-$304.14K–
Q2 FY2017CQ4 2016Nov 30, 2016-$202.89K–

More Biomerica figures

See a number that looks wrong?